Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

In the event of a dog bite, a person needs more than just the rabies vaccine. Experts highlight the importance of ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

A groundbreaking annual injection designed to protect against HIV has successfully passed its first safety trial, bringing new hope for long-term prevention.